Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc., is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company’s principal business is to acquire, or discover, develop, and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and commercial opportunity. The Company’s lead product is levosimendan, a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company is also developing Oxycyte, a systemic perfluorocarbon, or PFC, product, which is oxygen carrier for use in situations of acute ischemia. In addition, it also has developed a family of